A study evaluating bosutinib-exemestane combination vs. exemestane alone in women with HR+ HER2− breast cancer was terminated in 2012 due to unfavorable risk–benefit ratio of the study treatment (ClinicalTrials.gov identifier: NCT00793546). Here, ERBB2 is linked to breast carcinoma.